Limit this search to....

Pet/CT in Cancer: An Interdisciplinary Approach to Individualized Imaging
Contributor(s): Beheshti, Mohsen (Author), Langsteger, Werner (Author), Rezaee, Alireza (Author)
ISBN: 0323485677     ISBN-13: 9780323485678
Publisher: Elsevier
OUR PRICE:   $98.99  
Product Type: Hardcover - Other Formats
Published: June 2017
Qty:
Temporarily out of stock - Will ship within 2 to 5 weeks
Additional Information
BISAC Categories:
- Medical | Radiology, Radiotherapy & Nuclear Medicine
- Medical | Oncology - General
- Medical | Diagnostic Imaging - General
Dewey: 616.994
LCCN: 2017285302
Physical Information: 0.7" H x 7.3" W x 9.2" (1.60 lbs) 276 pages
 
Descriptions, Reviews, Etc.
Publisher Description:

Edited, authored, and reviewed by an expert team of oncologists and nuclear physicians/radiologists, this one-of-a-kind title helps you make the most of the critical role PET/CT plays in cancer staging and therapeutic responses to individualized treatments. Drs. Mohsen Beheshti, Werner Langsteger, and Alireza Rezaee place an emphasis on cutting-edge research and evidence-based practice, ensuring that you're up to date with every aspect of this fast-changing field. For each tumor entity, you'll find authoritative discussions of background, pathology, common pattern of spread, TNM classification, clinical guidelines, discussion, evidence-based recommendations, key points, and pitfalls.

  • Contains 130 teaching cases with high-quality PET/CT images.
  • Presents clear, practical guidance from multiple experts across subspecialties: nuclear medicine, oncology, oncologic surgery, radiation oncology, and clinical research.
  • Includes separate, comprehensive chapters on head and neck, lung, breast, esophageal/gastric, pancreas/neuroendocrine, colorectal, hepatobiliary, lymphoma, gynecologic, prostate, melanoma, and brain cancers.
  • Features short reviews of clinical aspects of different cancers, primary diagnostic procedures, and recommendations regarding PET/CT from ESMO and NCCN.

  • Helps to reveal positive outcomes or potential deficits or weaknesses in an individual plan of care, allowing for better outcomes in patient care, future cancer research, and application of radiotracers beyond 18F-FDG.